In addition to the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) such assulfasalazine, methotrexate, and hydroxychloroquine, some biological disease-modifying antirheumatic drugs (bDMARDs), mainly tumor necrosis factor inhibitors and interleukin-17 inhibitors, play a role in limiting the destruction of joints and improving patients' quality of life.